15 July, 2017
The stock has "Buy" rating by Bank of America on Wednesday, February 1. Hallmark Capital Management Inc. now owns 92,766 shares of the medical research company's stock valued at $15,977,000 after buying an additional 722 shares in the last quarter. The Company had previously anticipated second quarter revenues in the range of $1.940 billion to $1.960 billion, with constant currency growth to be in the range of 2.4% to 3.4%. It has outperformed by 8.36% the S&P500. Vetr raised Amgen from a "sell" rating to a "hold" rating and set a $174.10 price objective for the company in a research note on Monday, March 20th. Finally, Howe & Rusling Inc. increased its position in Amgen by 1.1% in the first quarter.
Amgen Inc. (NASDAQ:AMGN) shares were trading higher by 1.02 percent ($1.77) at $175.04 a piece in Thursday's session. (NASDAQ:AMGN) remains a cheap stock. Oppenheimer Holdings, Inc. reiterated an outperform rating and set a $189.00 price objective on shares of Amgen in a research report on Thursday, April 6th.
The stock is now moving with a Positive distance from 200-Day Simple Moving Average of about 9.1% and has a pretty decent Year to Date (YTD) Performance of 19.72% which means the stock is constantly adding to its value from previous fiscal year end price. The firm has a market cap of $130.26 billion, a P/E ratio of 16.82 and a beta of 1.36.
Traders and active investors could now look to a near-term trade toward $180 but respecting the earnings report scheduled for July 25. St. Johns Investment Management Company LLC increased its stake in Amgen by 5.1% in the second quarter. During the same period past year, the firm earned $2.90 earnings per share. Beck Mack & Oliver Limited Co reported 0.05% stake. Argus Research maintained the shares of AMGN in report on Monday, February 8 with "Buy" rating. (NASDAQ:AMGN) earned "Buy" rating by Deutsche Bank on Friday, July 31. Evanson Asset Mgmt Limited Company, a California-based fund reported 1,410 shares.
12/20/2016 - Amgen Inc. was downgraded to " by analysts at Credit Suisse.
Amgen Inc. (NASDAQ:AMGN), from Healthcare sector has been performing well. One research analyst has rated the stock with a sell rating, twelve have issued a hold rating, eleven have assigned a buy rating and three have given a strong buy rating to the company's stock. Crestpoint Management Limited Liability Com owns 8,000 shares or 0.59% of their USA portfolio. Spot Trading Lc holds 0.02% of its portfolio in Amgen, Inc.
Since May 24, 2017, it had 0 buys, and 2 insider sales for $1.02 million activity. (NASDAQ:AMGN). Mckinley Capital Mngmt Llc Delaware invested in 4,215 shares. Compton Management Ri has invested 0.48% in Amgen, Inc. Hancock Hldg has invested 0.12% of its portfolio in Amgen, Inc.
Investors sentiment decreased to 1.09 in 2016 Q4. 561.98 million shares or 1.23% less from 568.98 million shares in 2016Q3 were reported. (ZBH) have 205.08 million outstanding shares now held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders. Patton Cynthia M sold $451,164 worth of stock. Oakworth holds 0.04% in Amgen, Inc. Its down 0.17, from 1.26 in 2016Q3. It is negative, as 31 investors sold Dynavax Technologies Corporation shares while 28 reduced holdings.
Amgen (NASDAQ:AMGN) now has a trailing P/E of 16.63 while its forward P/E according to Thomson Reuters is 13.72. (NASDAQ:AMGN) traded up 1.41% on Friday, reaching $177.51. Ltd. raised its position in shares of Amgen by 426.2% in the fourth quarter. The Colorado-based Bsw Wealth Ptnrs has invested 0.17% in Amgen, Inc.
Capital International Inc, which manages about $18.21 billion and $804.03 million US Long portfolio, upped its stake in Nucor Corp (NYSE:NUE) by 13,500 shares to 14,740 shares, valued at $877,000 in 2016Q4, according to the filing. Amgen now has an average rating of "Buy" and a consensus target price of $185.65. The company was downgraded on Wednesday, July 20 by Goldman Sachs. (NASDAQ:AMGN). Virtu Fincl Limited Liability Co holds 0.04% or 2,653 shares in its portfolio. AMGN trades with a P/S ratio of 5.7. (NASDAQ:PAYX). Macquarie Grp Limited reported 20,600 shares. Wells Fargo initiated the stock with "Market Perform" rating in Friday, December 4 report. $569,541 worth of Amgen, Inc. The stock of Amgen, Inc. Finally, Morgan Stanley increased their price target on shares of Amgen from $183.00 to $184.00 and gave the company an "overweight" rating in a research report on Tuesday, June 13th.
Other equities analysts have also recently issued research reports about the stock.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.
